- West Pharmaceutical Services has appointed Michel Lagarde as President, Chief Executive Officer, and member of its Board of Directors, effective August 31, 2026.
- Lagarde will succeed Eric M. Green, who is retiring as President, CEO, and Board Chair, while Robert F. Friel will become Board Chair.
West Pharmaceutical Services, Inc. has announced the appointment of Michel Lagarde as President, Chief Executive Officer, and member of its Board of Directors, effective August 31, 2026. He will succeed Eric M. Green, who will retire from his roles as President, CEO, and Board Chair on the same date.
As part of the leadership transition, the company’s Board of Directors has elected Lead Independent Director Robert F. Friel to serve as Board Chair beginning August 31, 2026. The appointments follow a search process conducted by the Board to identify the company’s next chief executive.
Friel said Lagarde’s leadership experience, customer focus, and track record of building teams and creating long-term value made him well-suited for the role. The company stated that Lagarde will also join the Board of Directors when he assumes his new position.
“I’m honored to lead West into its next chapter of growth and to build on the company’s trusted reputation and enduring mission of improving patient health.”
Michel Lagarde, incoming President and CEO of West Pharmaceutical Services
